The compound you've described, **1-(4-bromophenyl)-N-(3,4-dichlorophenyl)-5-oxo-3-pyrrolidinecarboxamide**, is a synthetic organic molecule with a complex structure. It's important to note that this compound doesn't have a widely recognized name or common use.
**Structure:**
The molecule consists of:
* A **pyrrolidine ring** (a 5-membered ring with one nitrogen atom)
* A **carboxamide group** attached to the pyrrolidine ring
* A **phenyl ring** (a 6-membered ring with alternating single and double bonds) substituted with a bromine atom at the 4-position, attached to the nitrogen of the carboxamide group
* Another **phenyl ring** substituted with chlorine atoms at the 3 and 4 positions, attached to the nitrogen of the carboxamide group
**Potential Importance for Research:**
Given the complex structure and presence of multiple functional groups, this compound could be of interest for various research areas. However, without further context or information, it's difficult to pinpoint its exact significance. Here are some possibilities:
* **Pharmaceutical Research:** The presence of phenyl rings and a carboxamide group could indicate potential activity as a drug candidate. The specific substituents on the phenyl rings might influence binding affinity and interactions with biological targets.
* **Materials Science:** The compound could exhibit interesting physical properties, potentially leading to its application in material development.
* **Chemical Synthesis:** The molecule could serve as a building block or intermediate in the synthesis of other compounds with desired properties.
* **Biological Activity Studies:** Research might be conducted to investigate the compound's effects on biological systems, such as enzymes, receptors, or cells.
**To understand the true importance of this compound, more information is needed, such as:**
* The research context (e.g., drug discovery, material science)
* The specific properties being investigated (e.g., biological activity, physical properties)
* The researchers involved and their publications
Without this additional information, it's impossible to provide a definitive answer to why this compound is important for research.
ID Source | ID |
---|---|
PubMed CID | 3116961 |
CHEMBL ID | 1301129 |
CHEBI ID | 120529 |
Synonym |
---|
MLS000526254 , |
smr000116728 |
1-(4-bromo-phenyl)-5-oxo-pyrrolidine-3-carboxylic acid (3,4-dichloro-phenyl)-amide |
OPREA1_324695 |
OPREA1_654873 |
CHEBI:120529 |
AKOS000339612 |
MLS002535237 |
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide |
HMS2496H22 |
CHEMBL1301129 |
cid_3116961 |
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-oxo-3-pyrrolidinecarboxamide |
bdbm33640 |
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-keto-pyrrolidine-3-carboxamide |
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-oxidanylidene-pyrrolidine-3-carboxamide |
AKOS024284137 |
SR-01000358385-1 |
sr-01000358385 |
Q27208382 |
Class | Description |
---|---|
pyrrolidines | Any of a class of heterocyclic amines having a saturated five-membered ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 19.9526 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 70.7946 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 35.4813 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686979 |
Smad3 | Homo sapiens (human) | Potency | 22.3872 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
IDH1 | Homo sapiens (human) | Potency | 35.4813 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 16.3601 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
snurportin-1 | Homo sapiens (human) | Potency | 16.3601 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 16.3601 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 35.4813 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 14.1254 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
lamin isoform A-delta10 | Homo sapiens (human) | Potency | 22.3872 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
prothrombin | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.0010 | 3.3170 | 14.6895 | AID1215 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
streptokinase A precursor | Streptococcus pyogenes M1 GAS | EC50 (µMol) | 12.3180 | 0.0600 | 8.9128 | 130.5170 | AID1902; AID1914 |
Estrogen receptor | Rattus norvegicus (Norway rat) | EC50 (µMol) | 20.1340 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
Estrogen receptor beta | Rattus norvegicus (Norway rat) | EC50 (µMol) | 20.1340 | 0.0060 | 22.3670 | 130.5170 | AID1914 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |